vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and Oportun Financial Corp (OPRT). Click either name above to swap in a different company.
Oportun Financial Corp is the larger business by last-quarter revenue ($247.7M vs $180.9M, roughly 1.4× AVANOS MEDICAL, INC.). Oportun Financial Corp runs the higher net margin — 1.4% vs -0.7%, a 2.1% gap on every dollar of revenue. On growth, AVANOS MEDICAL, INC. posted the faster year-over-year revenue change (0.7% vs -1.3%). Over the past eight quarters, AVANOS MEDICAL, INC.'s revenue compounded faster (4.4% CAGR vs -0.5%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Oportun Financial Corp is a US-based fintech firm that provides accessible, responsible financial services including personal loans, credit cards, and savings products to underserved low-to-moderate income consumers, many with limited or no credit history, leveraging proprietary AI underwriting to deliver fair terms while mitigating operational risk.
AVNS vs OPRT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $247.7M |
| Net Profit | $-1.3M | $3.4M |
| Gross Margin | 47.5% | — |
| Operating Margin | 1.4% | 2.6% |
| Net Margin | -0.7% | 1.4% |
| Revenue YoY | 0.7% | -1.3% |
| Net Profit YoY | 99.7% | -61.0% |
| EPS (diluted) | $-0.02 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $247.7M | ||
| Q3 25 | $177.8M | $238.7M | ||
| Q2 25 | $175.0M | $234.3M | ||
| Q1 25 | $167.5M | $235.9M | ||
| Q4 24 | $179.6M | $250.9M | ||
| Q3 24 | $170.4M | $250.0M | ||
| Q2 24 | $171.7M | $250.4M | ||
| Q1 24 | $166.1M | $250.5M |
| Q4 25 | $-1.3M | $3.4M | ||
| Q3 25 | $-1.4M | $5.2M | ||
| Q2 25 | $-76.8M | $6.9M | ||
| Q1 25 | $6.6M | $9.8M | ||
| Q4 24 | $-397.3M | $8.7M | ||
| Q3 24 | $4.3M | $-30.0M | ||
| Q2 24 | $1.8M | $-31.0M | ||
| Q1 24 | $-900.0K | $-26.4M |
| Q4 25 | 47.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 52.6% | — | ||
| Q1 25 | 53.6% | — | ||
| Q4 24 | 54.6% | — | ||
| Q3 24 | 54.5% | — | ||
| Q2 24 | 55.7% | — | ||
| Q1 24 | 57.1% | — |
| Q4 25 | 1.4% | 2.6% | ||
| Q3 25 | 0.1% | 6.0% | ||
| Q2 25 | -42.6% | 4.3% | ||
| Q1 25 | 6.1% | 5.6% | ||
| Q4 24 | -233.0% | 89.6% | ||
| Q3 24 | 7.0% | -15.8% | ||
| Q2 24 | 3.7% | -19.6% | ||
| Q1 24 | 2.4% | -12.2% |
| Q4 25 | -0.7% | 1.4% | ||
| Q3 25 | -0.8% | 2.2% | ||
| Q2 25 | -43.9% | 2.9% | ||
| Q1 25 | 3.9% | 4.1% | ||
| Q4 24 | -221.2% | 200.1% | ||
| Q3 24 | 2.5% | -12.0% | ||
| Q2 24 | 1.0% | -12.4% | ||
| Q1 24 | -0.5% | -10.6% |
| Q4 25 | $-0.02 | $0.07 | ||
| Q3 25 | $-0.03 | $0.11 | ||
| Q2 25 | $-1.66 | $0.14 | ||
| Q1 25 | $0.14 | $0.21 | ||
| Q4 24 | $-8.64 | $0.26 | ||
| Q3 24 | $0.09 | $-0.75 | ||
| Q2 24 | $0.04 | $-0.78 | ||
| Q1 24 | $-0.02 | $-0.68 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $105.5M |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | $390.1M |
| Total Assets | $1.1B | $3.3B |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $105.5M | ||
| Q3 25 | $70.5M | $104.6M | ||
| Q2 25 | $90.3M | $96.8M | ||
| Q1 25 | $97.0M | $78.5M | ||
| Q4 24 | $107.7M | $60.0M | ||
| Q3 24 | $89.0M | $71.8M | ||
| Q2 24 | $92.2M | $72.9M | ||
| Q1 24 | $75.8M | $69.2M |
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
| Q4 25 | $778.2M | $390.1M | ||
| Q3 25 | $778.0M | $383.9M | ||
| Q2 25 | $776.3M | $376.0M | ||
| Q1 25 | $839.4M | $366.1M | ||
| Q4 24 | $828.5M | $353.8M | ||
| Q3 24 | $1.2B | $327.6M | ||
| Q2 24 | $1.2B | $354.1M | ||
| Q1 24 | $1.2B | $382.0M |
| Q4 25 | $1.1B | $3.3B | ||
| Q3 25 | $1.1B | $3.2B | ||
| Q2 25 | $1.0B | $3.2B | ||
| Q1 25 | $1.1B | $3.2B | ||
| Q4 24 | $1.2B | $3.2B | ||
| Q3 24 | $1.7B | $3.3B | ||
| Q2 24 | $1.7B | $3.3B | ||
| Q1 24 | $1.7B | $3.3B |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $413.4M |
| Free Cash FlowOCF − Capex | $21.3M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 3.8% | — |
| Cash ConversionOCF / Net Profit | — | 121.45× |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $413.4M | ||
| Q3 25 | $14.0M | $99.0M | ||
| Q2 25 | $6.8M | $104.5M | ||
| Q1 25 | $25.7M | $101.0M | ||
| Q4 24 | $57.9M | $393.5M | ||
| Q3 24 | $23.0M | $108.5M | ||
| Q2 24 | $27.8M | $107.7M | ||
| Q1 24 | $-8.0M | $85.9M |
| Q4 25 | $21.3M | — | ||
| Q3 25 | $7.0M | — | ||
| Q2 25 | $-4.2M | — | ||
| Q1 25 | $19.0M | — | ||
| Q4 24 | $53.1M | — | ||
| Q3 24 | $20.0M | — | ||
| Q2 24 | $21.9M | — | ||
| Q1 24 | $-12.1M | — |
| Q4 25 | 11.8% | — | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | -2.4% | — | ||
| Q1 25 | 11.3% | — | ||
| Q4 24 | 29.6% | — | ||
| Q3 24 | 11.7% | — | ||
| Q2 24 | 12.8% | — | ||
| Q1 24 | -7.3% | — |
| Q4 25 | 3.8% | — | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | 6.3% | — | ||
| Q1 25 | 4.0% | — | ||
| Q4 24 | 2.7% | — | ||
| Q3 24 | 1.8% | — | ||
| Q2 24 | 3.4% | — | ||
| Q1 24 | 2.5% | — |
| Q4 25 | — | 121.45× | ||
| Q3 25 | — | 19.05× | ||
| Q2 25 | — | 15.20× | ||
| Q1 25 | 3.89× | 10.34× | ||
| Q4 24 | — | 45.04× | ||
| Q3 24 | 5.35× | — | ||
| Q2 24 | 15.44× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
OPRT
Segment breakdown not available.
